

Changing Winds in the Profession: A Time for Transformation

Anandi Law March 28, 2022

Discussion objectives

Define	Define current issues in pharmacy	
Discuss	Discuss the possible causes for the issues	
Illustrate	Illustrate the relationships within the U.S. health system	
Describe	Describe the reimbursement process	
Recall	Recall the history of PBM and identify its role today	
Describe	Describe impacts on pharmacies and the profession	
Incorporate	Incorporate possible solutions for transformation	

What is currently happening in the pharmacy world?

Community pharmacies are closing

Over 4800

Community pharmacies in CA

50% Independent pharmacies

Past 4 years...













1 in 6

Long term impact

Independent pharmacies

DrugChannels.com CEO and futurist, Adam Fein, projected that another 10,000 to 15,000 pharmacies will close in the next five years.



3 – **5** years

50% Survive













Foodland to close its 7 pharmacies, transfer all prescriptions to Longs Drugs

Honolulu-based Foodland Super Market Ltd. said it has agreed to transfer all prescriptions from its seven Foodland Pharmacies in Hawaii to CVS Health's Longs Drugs pharmacies. Foodland said the transfer will be done electronically and automatically to minimize disruption to customers. Jenai S. Wall, Foodland Chairman and CEO, said: "The decision to exit the pharmacy business was not an easy one for us. While compressed margins and rising costs have led to increasing losses, we were concerned about the impact any closure would have on our many loyal pharmacy customers and employees.

https://ihpl.llu.edu/blog/losing-access-care-your-pharmacy-closing

CVS Closing 900 Retail Stores Starting in 2022

CVS Health has a new strategy to meet evolving consumer needs, and it includes closing stores and creating new store formats.

Drugstore chain **Walgreens** said it would be closing an additional five stores in the city, bringing the number of shuttered locations to 22 in the past five years, according to <u>San Francisco Chronicle</u>. The company has cited "organized retail crime" for the closings.

"Is Walgreens closing stores because of theft or because of a preexisting business plan to cut costs and increase profits by consolidating stores and shifting customers to online purchases?"

Why are pharmacies closing?

LACK OF PAYMENT FOR PHARMACIST SERVICES

A SHIFT IN THE WAY DRUGS ARE PAID FOR BY **INSURANCE COMPANIES**

RPh Overqualified and underutilized

Reimbursement **1**






Why are pharmacies closing?

Reimbursement **1**




What is reimbursement? How does it work?



The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Prescription Drugs





What is PBM?

1968 Initiation (origin of PBM)


- Adjudicate Rx claims
- Manage data


Late 1980's Collaboration with Pharma

Manage formulary on behalf of health insurers


Now Increased influence in the pharmacy field

- Negotiate drug price and rebates with Pharma
- Determine the reimbursement rate for community pharmacy
- Manage data to give health insurers recommendations
- Impact prior authorization





PBMs have come under scrutiny for not paying pharmacies what the PBM is billing Medicaid for drug acquisition costs (price gouging). As a workaround, PBMs are using "clawbacks" or DIRs that charge pharmacies weeks or months after the prescription was dispensed, a transaction that is invisible to Medicaid managed care organizations.



Direct-Indirect Remuneration

What is DIR?


Idea is to pass along savings from the PBM or Plan D sponsor to Medicare which will in turn, lower premiums for patients.

<u>Issues</u>


- Retroactive fees
- Zero transparency
- Supposed calculation based on pharmacy performance metrics
- No accountability

Reimbursement

In theory reimbursement



Actual reimbursement



Other PBM strategies

- Setting co-pays higher than the cost of the drug in many cases
- 3 PBMs control 80% of the prescription market
- 3 PBMs rank 4th (CVS), 5th (United Health), and 13th (Cigna) on the Fortune 500 by revenue, all ahead of the highest ranked pharmaceutical company, yet very few people understand how they make their money
- PBMs receive kickbacks from drug manufacturers for favorable formulary placement
- Many PBM contracts have "gagged" pharmacists from discussing less expensive alternatives or even lower out of pocket costs by not using their insurance

Revenue: Product Acquisition cost + reimbursement + Cost of Dispensing Dispensing Fee (of the pharmacy) (from health plan) Inventory or Merchandise **Profit** Payroll Overheads

Impact on community pharmacy

Reimbursement



Job opportunity



Rx Volume per staff




PHARMACY

Difficulty maintaining profitability

Impact on community pharmacy

Pharmacies were open throughout the pandemic! Workload with COVID 1- testing, vaccination





Impact on patients

Pharmacy options |



Interaction with pharmacists





Pharmacy deserts. More provider visits?

Higher burden on PCP?

1 in 3 neighborhoods in large US cities are pharmacy deserts, study finds

Pharmacy deserts may limit COVID-19 vaccine access in communities of color

UCI study first to link disparities and 'pharmacy deserts' in California

Do we have too many pharmacists? NO

- 315,000 pharmacists serving 315M Americans
 - Less than 1/1000
- 209,000 primary care physicians
- 419,000 pharmacy techs



Impact on hospital

Admitted patients



Workflow for staff



Patient's wait time





More ER visits? More TOC? Prioritization of patient?

Impact – ambulatory care pharmacy

Need for clinics



Primary pharmacist interaction with patient





More clinics?

More clinical pharmacists?

Impact on student pharmacists

Community rotation sites



Community pharmacy jobs



Interest in pharmacy career





Potential increased difficulty paying off debt

Impact on academia

Applicants

Community rotation sites








Quality/fit of applicants?

Number of students per rotation site?

Shift in community pharmacy roles



How will the payment system change?

Possible scenario 1

PBM


Pharmacist-Created PBM

Pro

- Transparency
- Able to control monetary flow
- Able to self-regulate

<u>Con</u>

- Small retails need to network
- Greater burden on pharmacists
- Building bargaining power



Possible scenario 2

Transparency Rx Model

Pro


- Transparency
- Cheaper drug price for patients
- Increased trust between pharmacists and PCPs

Con

- Still need to manage high cost medications
- Burden of responsibility on relationship between pharmacists and PCPs



Transparency Rx Model



Possible scenario 3



Clinical pharmacists at PCP office

Pro

Dispensing is separate

Direct cooperation between PCP and RPh

Comprehensive care for patients

Con

Dispensing for acute conditions?





Possible scenario 4 Shared Risk VBP (ACOPP)




Pro

- Shared responsibility for patients
- Promotes collaboration

<u>Con</u>

- Success depends on buy-in
- Risk aspect is challenging to implement



Possible scenario 5 Pharmacist Network

PBM

<u>Pro</u>

- Pharmacist PRN (as needed)
- Allows pharmacists to transition into clinical roles

Con

- Investment
- Advertising utility of clinical pharmacists





Transformation

Practice

Payment

ATTITUDES!

Patients see
pharmacists – for
counseling and
monitoring

Pharmacists see expanded roles – but limited by time staffing and reimbursement

Physicians – see us helping but draw the line

What will help the Transformation

Branding and Visibility

- Add services to product
- Separate services from product

Allyship with HCP who endorse us

Policy – Standard of Care rather than Scope of Practice

Other ideas?

How can students help?

Fundraising

Rases awareness as well

Educate people!

- Other students
- Faculty
- Preceptors
- Pharmacists at work

Join organization

- Eg: APhA
- State orgs





CE Objectives

- Which of the following are reasons for community pharmacy closures?

 - Decreasing # patients
 Decreasing # prescriptions
 Fewer technicians

 - 4. Reimbursement
- 2. Which of the following is/are the impact of PBMs on pharmacies?

 1. Reduced profit margins

 - 3. Increased profits
 - 4. a and b
- Which of the following is(are) advantages of pharmacists working within a PCP office?

 - Continuity of care
 Pharmacist working directly with physicians on needed medications
 Alignment of pharmacist role with training

 - 4. All of the above
- The ACOPP model could help improve patient outcomes
 - 1. True
 - False
- Do patients want someone from health care check on them?

 - Yes, according to a recent survey
 No, they never want anyone checking on them

Claiming Credit

Submit Attendance

- If you have not participated in a VCU Health CE program in the past:
 - Go to vcu.cloud-cme.com to create an account make sure to add your cell phone number
- If you have participated before:
 - Text the course code to (804) 625-4041.
 The course code for this event is: 25379-25376

Complete Evaluation & Claim Credit

- Go to https://vcu.cloud-cme.com
 OR
- Sign in using email address used above
- Click "My CE"

Open the CloudCME app on device

Click "My Evaluations"

Click the name of the activity to Click "Evaluations and Certificates"

ceinfo@vcuhealth.org





Center for Pharmacy Practice Innovation (CPPI) Seminar - 3/28/2022

Speaker(s): Anandi V Law, PhD

Topic:

CPPI invites various health care professionals from around the country and globe to speak on issues relating to innovation in the health care space.

Please contact the Center for Pharmacy Practice Innovation to request a meeting password by clicking here.

Please click here to join the webinar

Meeting ID: : 972 0552 6057

Objective(s): Location: NA

Specialties: Cardiovascular Disease, Endocrinology, Diabetes and Metabolism, Family Practice, General Practice, Nutrition, Pharmacist, Public Health, Academic/Research, Dietitians, Pharmacy Technician, Cardiology

Faculty Disclosures:

Anandi V Law, PhD (Nothing to disclose - 03/01/2022)

Download Handout

Purpose or Objectives: At the conclusion of this activity, the participant will be able to:

- Review changes in health care delivery that likely impact pharmacy practice.
- Describe current trends in contemporary pharmacy practice as they relate to interprofessional collaboration.
- Discuss practice innovations designed to improve health outcomes.
- Discuss role delineation for pharmacists on the interprofessional health care team.

Date/Time: 3/28/2022 12:00:00 PM

Accreditation:



In support of improving patient care, VCU Health Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation(s):

0.75 ANCC contact hours.





This activity provides 0.75 contact hours of continuing education credit. ACPE Universal Activity Number (UAN): Pharmacist: JA4008237-0000-22-164-L04-P Technician: JA4008237-0000-22-164-L04-T

NOTE FOR PHARMACISTS: Upon closing of the online evaluation, VCU Health Continuing Education will upload the pharmacy-related continuing education information to CPE Monitor within 60 days. Per ACPE rules, VCU Health Continuing Education does not have access nor the ability to upload credits requested after the evaluation closes. It is the responsibility of the pharmacist or pharmacy technician to provide the correct information [NABP ePID and DOB (in MMDD format)] in order to receive credit for participating in a continuing education activity.

Disclosure of Commercial Support:

We acknowledge that no commercial or in-kind support was provided for this activity.

Disclosure of Financial Relationships:

VCU Health Continuing Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The following planners, moderators or speakers have the following financial relationship(s) with commercial interests to disclose:

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Dave Dixon, PharmD, FACC, FCCP, FNLA, BCACP, BCPS, CDE, CLS	Activity Director	Contracted Research-Boehringer Ingelheim Vetmedica GmbH - 08/04/2021
Anandi V Law, PhD	Faculty	Nothing to disclose - 03/01/2022
Dana Burns, DNP	Planning Committee	Nothing to disclose - 12/16/2021
Teresa M Salgado, MPharm, PhD	Planning Committee	Nothing to disclose - 10/25/2021
Evan Sisson, Pharm.D., MSHA, BCACP, CDE, FAADE	Planning Committee	Nothing to disclose - 11/18/2021